Stopping Wegovy and Mounjaro advice from UK GP meets BMJ data on fast regain

A UK GP has set out a three step plan for stopping Wegovy and Mounjaro without rapid weight gain, the Mirror reported on 9 November. Her advice on eating, exercise and meal planning meets firm numbers: a BMJ meta analysis published in January found that people regain weight quickly once these drugs stop. The GP works for an online clinic that sells weight loss medication. The report cites no trial of her three steps, and the review did not test any way of tapering off treatment.

What the GP told readers about stopping

Dr Ann Nainan, a GP quoted by the Mirror, said people should not stop weight loss injections abruptly. She said they should speak to a healthcare professional first and come off the medicine over a period of time. Stopping suddenly, she said, can carry health risks and may reverse the results people have achieved. She listed three habits for life after treatment: keep eating healthily, exercise regularly and plan meals for the week. She said healthy foods should form the bulk of the diet, with occasional treats allowed. She also suggested cooking in bulk to cut reliance on ready meals and fast food. The report gives no tapering schedule and names no study showing that these steps reduce regain.

Her employer matters for readers weighing the advice. She works for an online clinic that prescribes weight loss medication, and she advised readers to consult a health professional or a specialist at an online clinic. This story does not name the clinic. Her message on diet and activity matches general guidance, but the Mirror piece offers no data of its own. Readers saw similar warnings this month, when UK GPs cautioned against changing doses for Christmas. In both cases the advice came from individual doctors rather than a regulator or a trial. Decisions about stopping Wegovy and Mounjaro belong with the prescriber who knows a patient's history, including any diabetes treatment.

Weight regain after GLP 1 in the BMJ review

The strongest evidence behind the warning comes from a systematic review by University of Oxford researchers, published in The BMJ on 7 January 2026. The team pooled 37 studies with 9,341 adults who stopped weight management drugs after an average of 39 weeks of treatment. Across all drugs, from older orlistat to newer GLP 1 receptor agonists, weight rose steadily once treatment ended. For semaglutide and tirzepatide, the review reported regain of about 0.8 kg a month, twice the 0.4 kg average across all weight loss drugs. At that pace, the University of Oxford release projects a return to starting weight in about 1.5 years for the newer drugs. The Mirror, citing the same review, put average regain at 9.9 kg within a year, around two thirds of the weight lost.

For semaglutide and tirzepatide, the review reported regain of about 0.8 kg a month, twice the 0.4 kg average across all weight loss drugs.

This comparison covered all drugs, not weight regain after GLP 1 medicines alone: regain after stopping was faster than after diet and exercise programmes by about 0.3 kg a month, regardless of initial weight loss, the researchers said. Behavioural support given alongside the drugs was linked to greater weight loss but did not slow regain later. The authors flagged clear limits. Only eight studies covered the newer GLP 1 drugs, and their longest follow up was 12 months after stopping, so later figures are modelled projections. Few studies had a low risk of bias, and most were controlled trials rather than routine care. Readers who want to test such numbers can read weight loss trial headlines with a short set of questions in mind.

Blood sugar risks for people with diabetes

The GP's sharpest warning concerned blood sugar. Many people given these medicines have prediabetes or type 2 diabetes, she said, and stopping suddenly can lead to spikes and unstable glucose levels. "This may result in medical treatment for the changes in blood sugar being required if left unmanaged," she told the Mirror. The BMJ review adds context. It found that HbA1c, fasting glucose, blood pressure, cholesterol and triglycerides improved during treatment. Those markers were estimated to return to baseline within about 1.4 years of stopping, according to the Oxford team. The published summaries of the review do not report short term glucose swings in the weeks after a final dose, so they neither confirm nor size that specific risk.

For people who use these medicines to manage diabetes, stopping is a change in diabetes care, not only in weight care. The GP said it "could be dangerous to stop suddenly" for anyone taking medicines that affect blood sugar levels. A BMJ Group summary of the paper said that around half of people with obesity are estimated to stop GLP 1 drugs within 12 months. That makes life after stopping Wegovy and Mounjaro a common situation, not a rare one. A linked BMJ editorial by a US researcher said healthy diet and lifestyle should remain the foundation of obesity care, with these drugs used as adjuncts. No source checked for this story describes a tested tapering method, which leaves a gap for patients and doctors.

NHS weight management support after treatment

Access to NHS weight management support after the drugs stop is uneven. The Oxford team noted that NICE quality standards recommend support for at least one year after treatment ends. According to the Mirror, GPs can refer people onward to dietitians, specialist services or a free digital programme run by the NHS over 12 weeks. The Oxford release also estimates that nine in ten people using weight loss medicines in the UK buy them privately, often without the clinical oversight and behavioural support that come with NHS prescribing. Senior author Dimitrios Koutoukidis said NICE's early cost estimates assumed weight would return over two to three years, while the new data point to about 18 months.

Habits after stopping also shift. NielsenIQ data reported here last month found that grocery baskets drift back toward the patterns of non users within six to 11 months. That fits a suggestion from Koutoukidis that people who lose weight on drugs may not build the practical skills that help keep it off. Lead author Sam West said obesity is a chronic, relapsing condition and that the findings do not reflect a failing of the medicines. Two questions remain open. The sources checked here hold no data beyond 12 months after stopping semaglutide or tirzepatide, and no trial has tested the GP's three step plan against usual care.

Conclusion

The GP's three steps for stopping Wegovy and Mounjaro are general lifestyle advice from a doctor at a commercial clinic, not a tested method. The BMJ meta analysis gives the firmer picture: average regain of about 0.8 kg a month after semaglutide and tirzepatide, with weight projected to return in about 1.5 years. Evidence beyond 12 months is thin, and no source here tests a taper. People with diabetes face added blood sugar questions. This report is research framing only and not medical advice.